Human FRA-1 Antibody

Detection of Human FRA‑1 by Western Blot.

Western blot shows lysates of A172 human glioblastoma cell line untreated (-) or treated (+) with 100 ng/mL Recombinant Human EGF (Catalog # 236-EG) for 18 hours. PVDF membrane was probed with 0.2 µg/mL of Goat Anti-Human FRA-1 Polyclonal Antibody (Catalog # AF4935), followed by HRP-conjugated Anti-Goat IgG Secondary Antibody (Catalog # HAF109). A specific band was detected for FRA-1 at approximately 45 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1.

FRA‑1 in Human Melanoma.

FRA-1 was detected in immersion fixed paraffin-embedded sections of human melanoma using Goat Anti-Human FRA-1 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF4935) at 3 µg/mL overnight at 4 °C. Before incubation with the primary antibody, tissue was subjected to heat-induced epitope retrieval using Antigen Retrieval Reagent-Basic (Catalog # CTS013). Tissue was stained using the Anti-Goat HRP-DAB Cell & Tissue Staining Kit (brown; Catalog # CTS008) and counterstained with hematoxylin (blue). Specific staining was localized to nuclei. View our protocol for Chromogenic IHC Staining of Paraffin-embedded Tissue Sections.

Detection of FRA-1 by Western Blot

Impact of SMARCA4 and FOSL1 on tumor growth in vivo and clinical implications in LUAD.A Tumor volume of Ctrl cells or SMARCA4-expressing clone #3-derived xenograft tumors treated with either DMSO or ACBI1 (10 mg/kg). Ctrl group (n = 4), SMARCA4 group (n = 5). B Tumor weight of Ctrl cells or SMARCA4-expressing clone #3-derived xenograft tumors treated with either DMSO or ACBI1 (10 mg/kg). Ctrl group (n = 4), SMARCA4 group (n = 5). C Images showing xenografted tumors derived from Ctrl cells and SMARCA4-expressing clone #3 treated with either DMSO or ACBI1 (10 mg/kg). Ctrl group (n = 4), SMARCA4 group (n = 5). D Western blot analysis of SMARCA4 and FOSL1 in Ctrl cells or SMARCA4-expressing clone #3-derived xenograft tumors treated with either DMSO or ACBI1 (10 mg/kg). beta -actin was used as a loading control. E Overall survival of LUAD patients was evaluated using Kaplan-Meier plotter according to expression of FOSL1 (left), SMARCA4 and FOSL1 (right). Probe set: SMARCA4 (214360_at), FOSL1 (204420_at). Two-way ANOVA with Tukey’s post hoc multiple comparisons test (A, B). Data from in vivo experiments are presented as the mean ± SEM for tumor growth and the mean ± SD for tumor weight. *p < 0.05, ****p < 0.0001, ns, not significant. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/42010258), licensed under a CC-BY license. Not internally tested by R&D Systems.